Brainstorm Cell Therapeutics, Inc. (BCLI)’s stock is trading at $0.65 at the moment marking a rise of 14.17% from the last session close. As of this writing, shares are priced at -81.19% less than their 52-week high of $3.46, and 385.63% over their 52-week low of $0.13. Based on the past 30-day period, the stock price is -12.91% below the high and +155.70% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, BCLI’s SMA-200 is $0.8453.
How does Brainstorm Cell Therapeutics, Inc. (BCLI) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 1 brokerage firms that recommend the stock as a Hold. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 3.00 in simple terms.
Brainstorm Cell Therapeutics, Inc. (BCLI): Earnings History
If we examine Brainstorm Cell Therapeutics, Inc.’s recent earnings history, in the last quarter ended on 6/29/2023, it posted adjusted earnings per share of -$0.27, beating the consensus of -$0.15. In other words, it beat the consensus by -$0.12, resulting in a -80.00% surprise. In the 3 months period before the previous quarter which was closed on 6/29/2023, the stock recorded adjusted earnings per share of -$0.27 in contrast with the Outlook of -$0.15. That was a difference of -$0.12 and a surprise of -80.00%.
Brainstorm Cell Therapeutics, Inc. (BCLI): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 1 different analysts, who are expecting earnings to fall in between the range of -0.15 and -0.15 with an average Earnings Estimate of -0.15 which is in contrast with the last year earnings estimate of -0.14 and also replicates -7.14% growth rate year over year.
Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) Ownership Details
I will give a breakdown of the key shareholders in Brainstorm Cell Therapeutics, Inc. (BCLI). Recent figures show that the company’s insiders hold 17.86% of shares. A total of 55 institutional investors hold shares in the company, making 8.25% of its stock and 10.04% of its float.
Dec 30, 2023, it was reported that the Company’s largest institutional holder is Vanguard Group Inc holding total of 1.42 million shares that make 2.91% of the company’s total number of shares and are currently priced at 0.9 million.
The securities firm Blackrock Inc. holds 0.47 million shares of BCLI, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.95%, and the holding percentage of shares is valued at 0.29 million.
An overview of Brainstorm Cell Therapeutics, Inc.’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Brainstorm Cell Therapeutics, Inc. (BCLI) traded 1,033,160 shares per day, with a moving average of $0.3862 and price change of +0.3315. With the moving average of $0.3626 and a price change of +0.3724, about 888,532 shares changed hands on average over the past 50 days. Finally, BCLI’s 100-day average volume is 2,012,842 shares, alongside a moving average of $0.2953 and a price change of +0.5413.
